Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been assigned an average recommendation of "Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.80.

A number of research firms recently issued reports on ZURA. Leerink Partners initiated coverage on Zura Bio in a research note on Monday, November 4th. They issued an "outperform" rating and a $15.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research report on Friday, October 18th. Chardan Capital decreased their price objective on Zura Bio from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. Piper Sandler reissued an "overweight" rating and issued a $26.00 target price on shares of Zura Bio in a research note on Thursday, September 19th. Finally, HC Wainwright restated a "neutral" rating and issued a $5.00 target price on shares of Zura Bio in a report on Monday, November 18th.

Zura Bio Stock Up 1.7 %

ZURA traded up $0.05 during trading on Friday, reaching $3.05. 162,455 shares of the stock were exchanged, compared to its average volume of 326,774. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35. The business's 50 day moving average price is $4.04 and its two-hundred day moving average price is $4.00.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Parvinder Thiara sold 1,001,633 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 2.42 % decrease in their position. The disclosure for this sale can be found here. 22.10% of the stock is owned by corporate insiders.

Institutional Trading of Zura Bio

A number of institutional investors and hedge funds have recently bought and sold shares of ZURA. Braidwell LP acquired a new position in Zura Bio during the third quarter valued at approximately $10,040,000. Point72 Asset Management L.P. acquired a new position in shares of Zura Bio during the 2nd quarter valued at $8,446,000. Great Point Partners LLC boosted its position in Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock worth $16,248,000 after purchasing an additional 1,884,501 shares during the period. Armistice Capital LLC increased its holdings in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after purchasing an additional 876,000 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Zura Bio in the 3rd quarter valued at $2,999,000. Institutional investors and hedge funds own 61.14% of the company's stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.